A 12-week, randomized, subject and investigator blind, placebo-controlled trial to evaluate the effect of CP-866,087 on weight loss in obese, otherwise healthy adult subjects
Phase of Trial: Phase II
Latest Information Update: 30 Oct 2008
At a glance
- Drugs CP 866087 (Primary)
- Indications Obesity
- Focus Biomarker; Therapeutic Use
- Sponsors Pfizer
- 31 Aug 2018 Biomarkers information updated
- 30 Oct 2008 Actual patient number (94) added as reported by ClinicalTrials.gov.
- 19 Feb 2008 Status changed from recruiting to completed.